Correlation between the efficacy of lamotrigine and the serum lamotrigine level during the remission phase of acute bipolar II depression: A naturalistic and unblinded prospective pilot study

Akiyoshi Kikkawa, Yoshihisa Kitamura, Tetsuya Aiba, Koichi Hiraki, Toshiaki Sendo

Research output: Contribution to journalArticle

Abstract

Lamotrigine has acute antidepressant effects in patients with bipolar disorder. However, there is little information regarding appropriate serum levels of lamotrigine and the time until remission after the start of lamotrigine therapy in patients with bipolar II depression. This was a naturalistic and unblinded prospective pilot study. Twelve patients' depressive symptoms were evaluated using the Montgomery-Åsberg Depression Rating Scale (MADRS) at the start of treatment and at the time of remission, and blood samples were obtained at the time of remission. Mahalanobis distance was used to analyze the relationship between the MADRS improvement rate and the serum lamotrigine level. Furthermore, we calculated the Spearman's rank correlation coefficient for the relationship between the MADRS improvement rate and the serum lamotrigine level, and produced box plots of the serum lamotrigine level at remission and the time until remission. The Mahalanobis distance for the patient that was co-administered lamotrigine and valproic acid differed significantly from those of the other patients (p<0.001). There was no linear relationship between the serum lamotrigine level and the MADRS improvement rate among the patients that did not receive valproic acid. The median time from the start of lamotrigine therapy until remission was 6 weeks. The serum lamotrigine level does not have an important impact on the acute therapeutic effects of lamotrigine on bipolar II depression. In addition, we consider that different treatment options should be considered for non-responders who do not exhibit any improvement after the administration of lamotrigine for approximately 6 weeks.

Original languageEnglish
Pages (from-to)413-418
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume40
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Bipolar Disorder
Prospective Studies
Serum
Valproic Acid
lamotrigine
Depression
Therapeutic Uses
Therapeutics
Nonparametric Statistics
Antidepressive Agents

Keywords

  • Bipolar II depression
  • Lamotrigine
  • Mahalanobis distance
  • Montgomery-Åsberg Depression Rating Scale
  • Serum level

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

@article{321fbb3857a64d1fb97aafc09bf279da,
title = "Correlation between the efficacy of lamotrigine and the serum lamotrigine level during the remission phase of acute bipolar II depression: A naturalistic and unblinded prospective pilot study",
abstract = "Lamotrigine has acute antidepressant effects in patients with bipolar disorder. However, there is little information regarding appropriate serum levels of lamotrigine and the time until remission after the start of lamotrigine therapy in patients with bipolar II depression. This was a naturalistic and unblinded prospective pilot study. Twelve patients' depressive symptoms were evaluated using the Montgomery-{\AA}sberg Depression Rating Scale (MADRS) at the start of treatment and at the time of remission, and blood samples were obtained at the time of remission. Mahalanobis distance was used to analyze the relationship between the MADRS improvement rate and the serum lamotrigine level. Furthermore, we calculated the Spearman's rank correlation coefficient for the relationship between the MADRS improvement rate and the serum lamotrigine level, and produced box plots of the serum lamotrigine level at remission and the time until remission. The Mahalanobis distance for the patient that was co-administered lamotrigine and valproic acid differed significantly from those of the other patients (p<0.001). There was no linear relationship between the serum lamotrigine level and the MADRS improvement rate among the patients that did not receive valproic acid. The median time from the start of lamotrigine therapy until remission was 6 weeks. The serum lamotrigine level does not have an important impact on the acute therapeutic effects of lamotrigine on bipolar II depression. In addition, we consider that different treatment options should be considered for non-responders who do not exhibit any improvement after the administration of lamotrigine for approximately 6 weeks.",
keywords = "Bipolar II depression, Lamotrigine, Mahalanobis distance, Montgomery-{\AA}sberg Depression Rating Scale, Serum level",
author = "Akiyoshi Kikkawa and Yoshihisa Kitamura and Tetsuya Aiba and Koichi Hiraki and Toshiaki Sendo",
year = "2017",
doi = "10.1248/bpb.b16-00725",
language = "English",
volume = "40",
pages = "413--418",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Correlation between the efficacy of lamotrigine and the serum lamotrigine level during the remission phase of acute bipolar II depression

T2 - A naturalistic and unblinded prospective pilot study

AU - Kikkawa, Akiyoshi

AU - Kitamura, Yoshihisa

AU - Aiba, Tetsuya

AU - Hiraki, Koichi

AU - Sendo, Toshiaki

PY - 2017

Y1 - 2017

N2 - Lamotrigine has acute antidepressant effects in patients with bipolar disorder. However, there is little information regarding appropriate serum levels of lamotrigine and the time until remission after the start of lamotrigine therapy in patients with bipolar II depression. This was a naturalistic and unblinded prospective pilot study. Twelve patients' depressive symptoms were evaluated using the Montgomery-Åsberg Depression Rating Scale (MADRS) at the start of treatment and at the time of remission, and blood samples were obtained at the time of remission. Mahalanobis distance was used to analyze the relationship between the MADRS improvement rate and the serum lamotrigine level. Furthermore, we calculated the Spearman's rank correlation coefficient for the relationship between the MADRS improvement rate and the serum lamotrigine level, and produced box plots of the serum lamotrigine level at remission and the time until remission. The Mahalanobis distance for the patient that was co-administered lamotrigine and valproic acid differed significantly from those of the other patients (p<0.001). There was no linear relationship between the serum lamotrigine level and the MADRS improvement rate among the patients that did not receive valproic acid. The median time from the start of lamotrigine therapy until remission was 6 weeks. The serum lamotrigine level does not have an important impact on the acute therapeutic effects of lamotrigine on bipolar II depression. In addition, we consider that different treatment options should be considered for non-responders who do not exhibit any improvement after the administration of lamotrigine for approximately 6 weeks.

AB - Lamotrigine has acute antidepressant effects in patients with bipolar disorder. However, there is little information regarding appropriate serum levels of lamotrigine and the time until remission after the start of lamotrigine therapy in patients with bipolar II depression. This was a naturalistic and unblinded prospective pilot study. Twelve patients' depressive symptoms were evaluated using the Montgomery-Åsberg Depression Rating Scale (MADRS) at the start of treatment and at the time of remission, and blood samples were obtained at the time of remission. Mahalanobis distance was used to analyze the relationship between the MADRS improvement rate and the serum lamotrigine level. Furthermore, we calculated the Spearman's rank correlation coefficient for the relationship between the MADRS improvement rate and the serum lamotrigine level, and produced box plots of the serum lamotrigine level at remission and the time until remission. The Mahalanobis distance for the patient that was co-administered lamotrigine and valproic acid differed significantly from those of the other patients (p<0.001). There was no linear relationship between the serum lamotrigine level and the MADRS improvement rate among the patients that did not receive valproic acid. The median time from the start of lamotrigine therapy until remission was 6 weeks. The serum lamotrigine level does not have an important impact on the acute therapeutic effects of lamotrigine on bipolar II depression. In addition, we consider that different treatment options should be considered for non-responders who do not exhibit any improvement after the administration of lamotrigine for approximately 6 weeks.

KW - Bipolar II depression

KW - Lamotrigine

KW - Mahalanobis distance

KW - Montgomery-Åsberg Depression Rating Scale

KW - Serum level

UR - http://www.scopus.com/inward/record.url?scp=85017009770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017009770&partnerID=8YFLogxK

U2 - 10.1248/bpb.b16-00725

DO - 10.1248/bpb.b16-00725

M3 - Article

C2 - 28381796

AN - SCOPUS:85017009770

VL - 40

SP - 413

EP - 418

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 4

ER -